临床儿科杂志 ›› 2022, Vol. 40 ›› Issue (1): 67-.doi: 10.12372/jcp.2022.21e0627

• 文献综述 • 上一篇    下一篇

儿童耐碳青霉烯类肺炎克雷伯杆菌脓毒症研究进展

李佳珊综述, 赵瑞秋审校   

  1. 重庆医科大学附属儿童医院感染科 儿童发育疾病研究教育部重点实验室国家儿童 健康与疾病临床医学研究中心 儿童发育重大疾病国家国际科技合作基地 儿童感染免疫重庆市重点实验室(重庆 400014)
  • 出版日期:2022-01-15 发布日期:2022-01-11

Research progress of pediatric sepsis caused by carbapenem-resistant Klebsiella pneumoniae

Reviewer: LI Jiashan, Reviser: ZHAO Ruiqiu   

  1. Department of Pediatric Infection, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing 400014, China
  • Online:2022-01-15 Published:2022-01-11

摘要: 近年来,革兰阴性细菌对抗菌药物的耐药性已达到临界水平,耐碳青霉烯类肺炎克雷伯杆菌(CRKP)在 多国儿科病房的检出率逐年增加。CRKP脓毒症起病隐匿,缺乏特异临床表现,但进展迅速、致病性强、易出现多器官 衰竭等,危及患儿生命。碳青霉烯类抗菌药物仍是CRKP感染的主要治疗手段。目前也有关于新型抗生素的研究。文 章对CRKP脓毒症的临床研究进展进行综述。

关键词: 碳青霉烯类耐药; 肺炎克雷伯杆菌; 血流感染; 儿童

Abstract: In recent years, the resistance of gram-negative bacteria to antibiotics has reached a critical level, and the detection rate of carbapenem-resistant Klebsiella pneumoniae (CRKP) in pediatric wards in many countries has been increasing year by year. CRKP sepsis has an insidious onset and lacks specific clinical manifestations. However, CRKP sepsis is highly pathogenic, progresses rapidly, and is prone to multiple organ failure, which can endanger the lives of children. Carbapenem antibiotics are still the main treatment for CRKP infection, and new antibiotics are also being studied. This article reviews the clinical research progress of CRKP sepsis.

Key words: carbapenem resistance; Klebsiella pneumoniae; bloodstream infection; child